Abayawardana

Spearheads the commercial strategy and market expansion for Prollenium Medical Technologies' aesthetic portfolio across the Asia Pacific (APAC) region, driving growth for premium products, including the Revanesse line of Hyaluronic Acid (HA) dermal fillers.

Worked directly with the founders of the pioneering veterinary referral hospital in Singapore, optimising operations for 130+ staff. Oversaw the post-acquisition integration with Mars’ Pet Care division by facilitating and navigating transition challenges to position the hospital for further growth. - Project managed the design and construction of a 1,200 sq meter state-of-the-art new facility, overseeing the relocation from the old site and expansion of staff from 70+ to 130+ associates, and scaling from 3 to 7 speciality departments. - Managed and optimised performance for a multidisciplinary team of 130+ associates, by restructuring operations, expanding service offering and streamlining the client service team. Ensuring maintenance of the highest standards of patient care and operational productivity. - Project managed the design and construction of a 1,200 sq meter state-of-the-art new facility, overseeing the relocation from the old site and expansion of staff from 70+ to 130+ associates, and scaling from 3 to 7 speciality departments. Transforming it into a multi-disciplinary referral centre. Managed a P&L generating 26% YoY growth with approximately $15 million in annual revenue.

Drove strategic operations for Sinclair in North Asia & Pacific, significantly impacting the Aesthetic business across 6 countries including China, Korea, Taiwan, Japan, Hong Kong, Australia & India, and accounting for over 80% of APAC revenue. - Directed successful management of 3 core Aesthetic brands (Ellanse, Silhouette Soft, Perfectha) with a team of 33 (Singapore & Korea) achieving a 46% EBITDA margin and driving 27% of Sinclair's group revenue. - Engineered a 30% sales growth by negotiating strategic price increases with distributors in Taiwan, Japan, and Hong Kong. - Streamlined operations in South Korea, one of Asia’s leading Aesthetic markets by consolidating business with the setup of the direct affiliate, enhancing efficiency and profitability. - Pioneered and championed digital transformation projects to enhance partner and client experience (Partner Engagement & Event Portal) andDigital Insights led marketing strategies to strengthen clinic profitability.

Relocated to Singapore to lead development and execution of Sinclair’s APAC strategy, establishing regional operations. Built and managed a team overseeing 13 APAC countries, coordinating with indirect distributors and a direct affiliate in Korea across all Dermatology & Aesthetic product lines. - Directed operations across Asia Pacific with full commercial P&L responsibility, achieving >12M GBP in revenue and 46% EBITDA in 2019/2020, surpassing sales and profit goals. - Cultivated strong relationships with regional distributors and country teams to support successful product launches and training programs. - Launched the market expansion strategy for the Dermatology range (Atopiclair, Papulex, Sebclair, Kelocote) across 13 APAC Markets, including the successful launch of Kelocote in China and Japan.

Led and expanded the Oral Care and Dermatology portfolio, driving global market growth and widening the distributor network. Managed a team overseeing 80+ distributors across Europe, USA, Middle East, and APAC. Secured distribution rights for Dermatology in APAC with Invida Pharmaceuticals (now Menarini APAC), significantly impacting strategy and boosting share prices.

Spearheaded the market expansion strategy of Aloclair (Oral Care) in 32 countries, including successful entries into the UK, USA, Canada, Israel, Turkey, Korea, Indonesia, and Malaysia, as well as successful registration and launch of Decapinol in the USA.